
Sonia M Vallabh

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9011871/publications.pdf Version: 2024-02-01



SONIA M VALLARH

#	Article	IF	CITATIONS
1	Regional variability and genotypic and pharmacodynamic effects on PrP concentration in the CNS. JCI Insight, 2022, 7, .	2.3	11
2	Genetic counseling for prion disease: Updates and best practices. Genetics in Medicine, 2022, 24, 1993-2003.	1.1	11
3	Implications of new genetic risk factors in prion disease. Nature Reviews Neurology, 2021, 17, 5-6.	4.9	1
4	Novel quaternary structures of the human prion protein globular domain. Biochimie, 2021, 191, 118-125.	1.3	4
5	The Patient-Scientist's Mandate. New England Journal of Medicine, 2020, 382, 107-109.	13.9	3
6	Characterization of the Prion Protein Binding Properties of Antisense Oligonucleotides. Biomolecules, 2020, 10, 1.	1.8	186
7	Prion protein lowering is a disease-modifying therapy across prion disease stages, strains and endpoints. Nucleic Acids Research, 2020, 48, 10615-10631.	6.5	69
8	Multimodal small-molecule screening for human prion protein binders. Journal of Biological Chemistry, 2020, 295, 13516-13531.	1.6	14
9	Cerebrospinal fluid and plasma biomarkers in individuals at risk for genetic prion disease. BMC Medicine, 2020, 18, 140.	2.3	34
10	Towards a treatment for genetic prion disease: trials and biomarkers. Lancet Neurology, The, 2020, 19, 361-368.	4.9	60
11	Age at onset in genetic prion disease and the design of preventive clinical trials. Neurology, 2019, 93, e125-e134.	1.5	73
12	Prion protein quantification in human cerebrospinal fluid as a tool for prion disease drug development. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 7793-7798.	3.3	41
13	Domain-specific Quantification of Prion Protein in Cerebrospinal Fluid by Targeted Mass Spectrometry. Molecular and Cellular Proteomics, 2019, 18, 2388-2400.	2.5	22
14	Antisense oligonucleotides extend survival of prion-infected mice. JCI Insight, 2019, 4, .	2.3	80
15	Quantifying prion disease penetrance using large population control cohorts. Science Translational Medicine, 2016, 8, 322ra9.	5.8	289
16	Htt CAG repeat expansion confers pleiotropic gains of mutant huntingtin function in chromatin regulation. Human Molecular Genetics, 2015, 24, 2442-2457.	1.4	53